摘要
由于中药在生产和研发等诸多环节方面的特殊性,近年来有关中药不良事件的频发,导致人们对中药的安全性产生质疑,而加强中药上市后的风险评价至关重要。该文对中药上市后的风险因素进行了分析,包括药品质量风险、ADR不良反应风险以及不合理用药风险。根据风险因素分析可以构建中药上市后的风险评价指标体系,同时运用层次分析法和模糊评价相关理论,构建了中药上市后的层次模糊综合风险评价模型,可以对中药上市后的风险进行定量与定性分析,为中药上市后的风险管理提供了参考。
Due to the special nature of many aspects of traditional Chinese medicine in terms of production and research and development in recent years of Chinese medicine frequent adverse events, led people to question the safety of the medicine, and the importance of strengthening risk evaluation of traditional Chinese medicine on the market. In this paper, the risk factors listed Chinese medicine were analyzed, including the risk of drug quality, ADR risk of^adverse reactions and irrational drug risks. Analysis can build evaluation index system of venture after the traditional Chinese medicine market based on risk factors, but this paper, AHP and fuzzy evaluation theory, to build a comprehensive risk assessment model hierarchy fuzzy traditional Chinese medicine market, may risk after medicine market quantitatively and qualitative analysis of the market for the traditional Chinese medicine to improve the risk management reference.
出处
《辽宁中医药大学学报》
CAS
2016年第9期210-212,共3页
Journal of Liaoning University of Traditional Chinese Medicine
关键词
中药
不良反应
风险评价
层次分析法
模糊评价
traditional Chinese medicine
adverse effects
risk assessment
analytic hierarchy process
fuzzy evaluation
